biostudies-literatureUnknown7(51)Wang YXColorectal cancer (CRC) is the third most common cancer worldwide. Metastatic progression is a primary factor contributing to lethality of CRC patients. However, the molecular mechanisms forming early local invasion and distant metastatic colonies are still unclear and the present therapeutic approaches for CRC are unsatisfactory. Therefore, novel therapies targeting metastatic invasion that could prevent tumor spreading and recurrence are urgently needed. Our study showed that the decrease of miR-384 was found in 83.0% (83/100) CRC patients. And low-leveled expression of miR-384 was closely correlated with the invasive depth, lymph node and distant metastasis of CRC. Overexpression of miR-384 could inhibit the invasive and migrating abilities of CRC cells in vitro and the metastatic potenOncotarget84826-84838https://www.ebi.ac.uk/biostudies/studies/S-EPMC5356701biostudies-literatureMiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.PMC5356701Chen YRWang SYLiao WTJiao HLLiu SSWei WTDing YQLiang LQiu JFXiao ZYWang YXYe YPfalseMiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.Colorectal cancer (CRC) is the third most common cancer worldwide. Metastatic progression is a primary factor contributing to lethality of CRC patients. However, the molecular mechanisms forming early local invasion and distant metastatic colonies are still unclear and the present therapeutic approaches for CRC are unsatisfactory. Therefore, novel therapies targeting metastatic invasion that could prevent tumor spreading and recurrence are urgently needed. Our study showed that the decrease of miR-384 was found in 83.0% (83/100) CRC patients. And low-leveled expression of miR-384 was closely correlated with the invasive depth, lymph node and distant metastasis of CRC. Overexpression of miR-384 could inhibit the invasive and migrating abilities of CRC cells in vitro and the metastatic poten2016-01-01T00:00:00Z2016 Dec2025-04-04T14:33:22.093Z2019-03-27T02:39:00ZS-EPMC53567012776904110.18632/oncotarget.12704